ALEVE
What it isNonselective COX-1 and COX-2 inhibitor; pain and inflammation, notably gout and inflammatory arthritis.
Why this oneTwice-daily dosing from a long half-life, and the least cardiovascular signal among the traditional NSAIDs.
What limits itGI bleeding and kidney injury remain; it raises lithium exposure and can worsen hypertension or edema.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Rheumatoid arthritis, osteoarthritis, ankylosing spondylitis | Adults | 250, 375, or 500 mg BID | 250–500 mg BID | 1500 mg/day for limited periods (≤6 months) |
| Polyarticular juvenile idiopathic arthritis | Pediatric | ~10 mg/kg/day divided BID | ~10 mg/kg/day in 2 divided doses | Tablets not appropriate for children <50 kg |
| Pain, primary dysmenorrhea, acute tendonitis/bursitis | Adults | 500 mg once, then 250 mg every 6–8 h | 250 mg every 6–8 h PRN | 1250 mg/day |
| Acute gout | Adults | 750 mg once, then 250 mg every 8 h | 250 mg every 8 h until attack subsides |
Renal Not recommended in moderate-to-severe or severe renal impairment (CrCl <30 mL/min).
Hepatic Undefined (monitor; discontinue if liver disease develops).
Pregnancy Avoid at ≥30 weeks (premature ductus arteriosus closure); limit use 20–30 weeks (oligohydramnios/neonatal renal impairment).
Lactation Undefined.
⚠ BOXED WARNINGS
Cost, est. cash$10–$300/month
Generic entry1993
Legacy pregnancy categoryMultiple / indication-, trimester- or formulation-dependent
Defining liabilityGI bleeding, kidney injury, hypertension and fluid retention; many agents increase lithium concentrations.

Open Naproxen in the interactive console ↗

